A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors.

Trial Profile

A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs PKI 179 (Primary)
  • Indications Breast cancer; Colorectal cancer; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Dec 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top